General Information of This Antibody
Antibody ID
ANTI0FRRZM
Antibody Name
Anti-CD276 mAb
Synonyms
Anti-CD276 mAb
   Click to Show/Hide
Antigen Name
CD276 antigen (CD276)
 Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-CD276 mAb-MMAF [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
64.10%
Method Description
To evaluate the synergetic anti-NSCLC efficacy of CD276 mAb-MMAF, about 3 × 106 mouse LLC-FLuc cells were s.c. injected into C57BL mice to establish immunocompetent models. The mice were i.v. injected with saline (vehicle, control), 12 mg/kg anti-CD276 mAb (control), and 12 and 24 mg/kg anti-CD276 mAb-MMAF (n = 6). (12 mg/kg)
In Vivo Model H460-FLuc cells into nude mice model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
91.90%
Method Description
To evaluate the synergetic anti-NSCLC efficacy of CD276 mAb-MMAF, about 3 × 106 mouse LLC-FLuc cells were s.c. injected into C57BL mice to establish immunocompetent models. The mice were i.v. injected with saline (vehicle, control), 12 mg/kg anti-CD276 mAb (control), and 12 and 24 mg/kg anti-CD276 mAb-MMAF (n = 6). (24 mg/kg)
In Vivo Model H460-FLuc cells into nude mice model
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
32.5 nM
High CD276 expression (CD276 +++)
Method Description
The cytotoxicity assay was performed using human NSCLC cell line H460-FLuc and mouse LLC-FLuc. With different cell division rates, 3000 H460-FLuc cells or 1000 LLC-FLuc cells with 200 uL of RPMI-1640 or a DMEM complete growth medium were seeded into each well in the 96-well plates. The cells were incubated at 37 °C in a CO2 incubator for 24 h, followed by the addition of free MMAF or ADC at dosages of 0, 10, 20, 40, 80, 120, 160, and 200 nM. The 3- (4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Cell Proliferation Assay (MTT Assay) was performed following the biomanufacturer procedure after 5-day treatment. At the end of treatment, the spent medium was removed and replaced with 100 uL of the fresh culture medium supplemented with 10 uL of the MTT reagent in each well. After 2 h of incubation in the dark, 100 uL of the detergent reagent was added to each well until a purple color was developed. The OD value was read at 590 nm using a SpectraMax iD3 plate reader (San Jose, CA, USA), and IC50 values were calculated.

   Click to Show/Hide
In Vitro Model Lung large cell carcinoma H460 cells (Human) CVCL_0459
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
60.5 nM
Low CD276 expression (CD276+)
Method Description
The cytotoxicity assay was performed using human NSCLC cell line H460-FLuc and mouse LLC-FLuc. With different cell division rates, 3000 H460-FLuc cells or 1000 LLC-FLuc cells with 200 uL of RPMI-1640 or a DMEM complete growth medium were seeded into each well in the 96-well plates. The cells were incubated at 37 °C in a CO2 incubator for 24 h, followed by the addition of free MMAF or ADC at dosages of 0, 10, 20, 40, 80, 120, 160, and 200 nM. The 3- (4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Cell Proliferation Assay (MTT Assay) was performed following the biomanufacturer procedure after 5-day treatment. At the end of treatment, the spent medium was removed and replaced with 100 uL of the fresh culture medium supplemented with 10 uL of the MTT reagent in each well. After 2 h of incubation in the dark, 100 uL of the detergent reagent was added to each well until a purple color was developed. The OD value was read at 590 nm using a SpectraMax iD3 plate reader (San Jose, CA, USA), and IC50 values were calculated.

   Click to Show/Hide
In Vitro Model Malignant tumors of the mouse pulmonary system LCC cells (Mouse) CVCL_5653
References
Ref 1 A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)